TuHURA Biosciences Reports Q4 and Full Year 2025 Financial Results and Major Corporate Developments

Key Highlights for Shareholders and Investors

• Strong Execution in 2025: TuHURA Biosciences (NASDAQ: HURA) reported robust progress across its clinical and corporate programs in 2025, advancing multiple assets in its pipeline targeting cancer immunotherapy resistance.
• Strategic Appointment: The company engaged Craig Tendler, M.D., to provide Chief Medical Officer-level strategic and operational oversight of the clinical pipeline, notably the VISTA inhibiting antibody TBS-2025. His appointment brings extensive clinical development expertise and is expected to accelerate program milestones.
• Advancing VISTA and IFx-2.0 Programs: The VISTA program is targeting multiple key milestones in 2026, while the IFx-2.0 Phase 3 trial in front-line Merkel Cell Carcinoma (MCC) is on track to complete enrollment by mid-2027.
• Innovation in ADCs: TuHURA is advancing its first-in-class immune modulating antibody drug conjugate (ADC) program, with new preclinical proof-of-concept data expected at a scientific conference later in 2026.

Corporate Updates and Price-Sensitive Events

• Initiation of Phase 3 Accelerated Approval Trial for IFx-2.0: This randomized trial is for first-line treatment of advanced or metastatic MCC as adjunctive therapy to Keytruda® (pembrolizumab), being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. The primary endpoint is Overall Response Rate (ORR), qualifying for accelerated approval, with Progression Free Survival (PFS) as a key secondary endpoint that may convert accelerated to regular approval if confirmed.
• Phase 1b/2a Study Launch for IFx-2.0: A new trial explores IFx-2.0 in combination with Keytruda® for metastatic MCC of Unknown Primary Origin (MCCUP), administered via interventional radiology in deep-seated tumors.
• Acquisition of Kineta and VISTA Asset: TuHURA completed the acquisition of Kineta, gaining full rights to TBS-2025, a novel VISTA-inhibiting antibody, for \$10.5 million—potentially transformative for its immunotherapy pipeline.
• Capital Raised: The company raised \$21.2 million in gross proceeds through registered direct offerings and private placements, strengthening the balance sheet and supporting ongoing R&D.
• Delta Opioid Receptor (DOR) as a Novel Target: Cutting-edge data was presented at the American Society of Hematology (ASH), showing that DOR is expressed on myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). Inhibition of DOR could reverse immune suppression and overcome resistance to checkpoint inhibitors, potentially opening a new therapeutic avenue for cancer immunotherapies.

Upcoming Milestones with Potential to Move Share Price

• IFx-2.0 (Innate Immune Agonist):
  • 1H 2026: Anticipated Orphan Drug Designation in MCC (market exclusivity and pricing opportunity)
  • 2H 2026: Preliminary data from Phase 1b/2a study in MCCUP
  • 2H 2027: Topline Phase 3 results in advanced/metastatic MCC, a pivotal inflection point for the company
• TBS-2025 (VISTA Inhibiting Antibody):
  • June 2026: FDA meeting to discuss development plan in NPM1 mutated relapsed/refractory AML
  • 2H 2026: Initiation of Phase 1b/2 trial in AML
• ADC Platform:
  • 1H 2026: Selection of lead ADC candidate in AML
  • 2H 2026: Initiation of in vivo proof-of-concept studies and expected data presentations at key scientific meetings

Financial Summary and Capital Position

• Cash Position: \$3.6 million in cash and equivalents at December 31, 2025, with an additional \$7.5 million received in Q1 2026 from the 2025 registered direct offering.
• R&D Expenditure: \$20.5 million in 2025 (pro forma with Kineta: \$22.1 million), up from \$13.3 million in 2024 (pro forma: \$18.7 million).
• General & Administrative Expenses: \$7.6 million in 2025, up from \$3.9 million in 2024, reflecting scaling operations post-Kineta acquisition.
• Net Cash Outflows from Operations: (\$27.7) million in 2025, compared to (\$14.7) million in 2024.
• Net Cash from Financing Activities: \$19.9 million in 2025, down from \$29.7 million in 2024.
• Shares Outstanding: Approximately 52.9 million as of December 31, 2025.

About TuHURA Biosciences

TuHURA Biosciences is a clinical-stage immuno-oncology company focused on overcoming primary and acquired resistance to cancer immunotherapy. Its lead asset, IFx-2.0, is an innate immune agonist in a pivotal Phase 3 trial for MCC as an adjunct to Keytruda®. The company recently acquired Kineta and its VISTA-inhibiting antibody TBS-2025, and is advancing novel ADCs targeting myeloid-derived suppressor cells.

For more information, see www.tuhurabio.com.

Conclusion for Investors

Shareholders should closely watch TuHURA’s upcoming clinical and regulatory milestones in 2026 and 2027, as these could be significant catalysts for the company’s valuation. The completion of the Kineta acquisition, new capital raised, and upcoming data readouts position TuHURA for potentially transformational events in the next 12-24 months.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties. Investors should review the company’s SEC filings and consult their financial advisor before making investment decisions.

View TuHURA Biosciences, Inc./NV Historical chart here